On March 30, 2026, Lumosa Therapeutics announced an amendment to the exclusive licensing agreement for LT3001 in China with Shanghai Pharmaceuticals Holding Co., Ltd.
Shanghai Pharma retains the rights to develop, manufacture, register, market, and promote LT3001 in China. Shanghai Pharma handles the costs for subsequent development, commercialization, and promotion.
The amendment covers a seamless Phase 2/3 bridging trial. Lumosa shares part of the trial development costs through milestone payments.
The Company stated that this matter has positive long- and short-term effects on operations.